Limits...
TOX expression in cutaneous B-cell lymphomas.

Schrader AM, Jansen PM, Willemze R - Arch. Dermatol. Res. (2016)

Bottom Line: Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas.In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL.The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Leiden University Medical Center, P.O. box 9600, 2300 RC, Leiden, The Netherlands. a.m.r.schrader@lumc.nl.

ABSTRACT
Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas. In a recent study, TOX expression was noted unexpectedly in the follicle center (germinal center) B-cells of reactive lymph nodes and tonsils, used as external controls. To evaluate whether TOX is also expressed by cutaneous B-cell lymphomas, TOX immunohistochemistry was performed on skin biopsies of 44 patients with primary and secondary cutaneous B-cell proliferations. TOX was expressed not only in the reactive follicle center cells of lymph nodes, tonsils, cutaneous lymphoid hyperplasia, and primary cutaneous marginal zone lymphomas, but also by the neoplastic follicle center cells of 16/17 patients with primary cutaneous follicle center lymphoma (PCFCL) and 7/7 patients with cutaneous manifestations of systemic follicular lymphoma (FL). Notably, TOX showed a very similar expression pattern as BCL6, a marker of germinal center B-cells. In 4/10 patients with a BCL6(+) primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL,LT) and in 2/2 patients with a secondary cutaneous BCL6(+) diffuse large B-cell lymphoma (DLBCL), TOX was expressed by more than 50 % of the neoplastic B-cells. In contrast, in 3/3 BCL6(-) PCDLBCL,LT, TOX was completely negative or weakly expressed by a minor proportion of the neoplastic B-cells. In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL. The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

No MeSH data available.


Related in: MedlinePlus

Histopathology of a patient with primary cutaneous follicle center lymphoma with a follicular growth pattern. Hematoxylin–eosin staining (a) shows nodular dermal infiltrates of large centrocytes (insets), which stain positively for BCL6 (b) and TOX (c). (a–c ×100, and insetsa–c ×400)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940438&req=5

Fig2: Histopathology of a patient with primary cutaneous follicle center lymphoma with a follicular growth pattern. Hematoxylin–eosin staining (a) shows nodular dermal infiltrates of large centrocytes (insets), which stain positively for BCL6 (b) and TOX (c). (a–c ×100, and insetsa–c ×400)

Mentions: TOX was expressed by the neoplastic follicle center cells in 16/17 patients (94 %) with PCFCL and in 7/7 patients (100 %) with skin lesions of systemic FL (Fig. 2). In these cases, TOX and BCL6 also showed a very similar staining pattern. Remarkably, in one case of PCFCL with a diffuse growth pattern, the neoplastic follicle center cells were positive for BCL6 but completely negative for TOX, while TOX was expressed by scattered small lymphocytes, serving as a useful internal control.Fig. 2


TOX expression in cutaneous B-cell lymphomas.

Schrader AM, Jansen PM, Willemze R - Arch. Dermatol. Res. (2016)

Histopathology of a patient with primary cutaneous follicle center lymphoma with a follicular growth pattern. Hematoxylin–eosin staining (a) shows nodular dermal infiltrates of large centrocytes (insets), which stain positively for BCL6 (b) and TOX (c). (a–c ×100, and insetsa–c ×400)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940438&req=5

Fig2: Histopathology of a patient with primary cutaneous follicle center lymphoma with a follicular growth pattern. Hematoxylin–eosin staining (a) shows nodular dermal infiltrates of large centrocytes (insets), which stain positively for BCL6 (b) and TOX (c). (a–c ×100, and insetsa–c ×400)
Mentions: TOX was expressed by the neoplastic follicle center cells in 16/17 patients (94 %) with PCFCL and in 7/7 patients (100 %) with skin lesions of systemic FL (Fig. 2). In these cases, TOX and BCL6 also showed a very similar staining pattern. Remarkably, in one case of PCFCL with a diffuse growth pattern, the neoplastic follicle center cells were positive for BCL6 but completely negative for TOX, while TOX was expressed by scattered small lymphocytes, serving as a useful internal control.Fig. 2

Bottom Line: Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas.In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL.The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Leiden University Medical Center, P.O. box 9600, 2300 RC, Leiden, The Netherlands. a.m.r.schrader@lumc.nl.

ABSTRACT
Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas. In a recent study, TOX expression was noted unexpectedly in the follicle center (germinal center) B-cells of reactive lymph nodes and tonsils, used as external controls. To evaluate whether TOX is also expressed by cutaneous B-cell lymphomas, TOX immunohistochemistry was performed on skin biopsies of 44 patients with primary and secondary cutaneous B-cell proliferations. TOX was expressed not only in the reactive follicle center cells of lymph nodes, tonsils, cutaneous lymphoid hyperplasia, and primary cutaneous marginal zone lymphomas, but also by the neoplastic follicle center cells of 16/17 patients with primary cutaneous follicle center lymphoma (PCFCL) and 7/7 patients with cutaneous manifestations of systemic follicular lymphoma (FL). Notably, TOX showed a very similar expression pattern as BCL6, a marker of germinal center B-cells. In 4/10 patients with a BCL6(+) primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL,LT) and in 2/2 patients with a secondary cutaneous BCL6(+) diffuse large B-cell lymphoma (DLBCL), TOX was expressed by more than 50 % of the neoplastic B-cells. In contrast, in 3/3 BCL6(-) PCDLBCL,LT, TOX was completely negative or weakly expressed by a minor proportion of the neoplastic B-cells. In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL. The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

No MeSH data available.


Related in: MedlinePlus